Proudly Manufacturing Quality Immunoassay Kits In The Greater Philadelphia Area Since 1988

Assay Kits for Reliable Analyte Measurement

Find ELISA Kits and supporting assays to measure a range of analytes in urine and other biofluids, all made to exacting Exocell standards. 

FOR RESEARCH USE ONLY

Target Analytes 

Disease Area

Why choose Exocell Assays from Ethos?

With scientific roots in nephrology dating back to Exocell’s founding in 1988 by Margo Cohen, MD. Ph.D., Exocell assays were originally developed to advance research into complications from diabetes that affect the kidneys. From the original Albuwell ELISA and Creatinine Companion Kits, which have become the gold standard assays for microalbuminuria measurement, the analyte list has expanded to include biomarkers for other conditions that frequently co-occur with diabetes. Regardless of the analyte, each kit embodies Exocell’s (and now Ethos’) commitment to accurate and precise measurement, with reagents and assays designed to maximize quality and ease-of-use while minimizing variability. Find the right assay for your needs and learn more using the links below.

Featured papers: See how Exocell Assays advance research

Exocell Albuwell M ELISA Kit:

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
Tammela T et al. Nature. 2008 Jul 31;454(7204):656-60. doi: 10.1038/nature07083.

 

Exocell Creatinine Companion:

Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice
Hanayama R et al. Science. 2004 May 21;304(5674):1147-50.

 

Exocell Albuwell M ELISA Kit, The Creatinine Companion:

Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction
Qi W et al. Nat Med. 2017 Jun;23(6):753-762. doi: 10.1038/nm.4328.

About Ethos

Ethos Biosciences was formed in 2018 as a subsidiary of Ott Scientific focused on the design, development, and manufacture of high-quality, easy-to-use assay kits, reagents, and services. In November 2018, we acquired the Exocell™ diagnostics operation from Glycadia, Inc., as a first step in assembling a world-class product catalog, and look forward to further expanding our offerings.

With the Exocell acquisition, we not only incorporated the widely-cited products, many of which are considered the gold-standard assay in their respective areas, we’ve kept the entire operation.  This means that current Exocell customers will continue to receive the same industry-leading products, services, and support that they’ve depended on since the company’s founding in 1988 by Margo Cohen, MD. Ph.D.